Answers are grounded in this paper and cite their sources.
Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated. We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine kinase-phosphate correlation, cholesterol and triglyceride values.
No takes yet. Share an insight, caveat, or question.
Franceschino et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: